Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.

Wästerlid, Tove LU ; Brown, P N ; Hagberg, Oskar LU ; Hagberg, H ; Pedersen, L M ; D'Amore, F and Jerkeman, Mats LU (2013) In Annals of Oncology 24(7). p.1879-1886
Abstract
BackgroundStandard treatment of adult Burkitt lymphoma is not defined due to the lack of randomised trials. In this situation, population-based data may represent a useful contribution in order to identify an optimal treatment strategy.Patients and methodsThe aims of this study were to investigate the outcome for adult HIV-negative BL with different chemotherapy regimens, and to assess possible improvement within the time frame of the study. The study population was identified through the Swedish and Danish lymphoma registries 2000-2009.ResultsA total of 258 patients were identified. Since 2000, overall survival (OS) improved significantly only for younger patients (<65 years). Intensive regimens such as the Berlin-Frankfurt-Münster,... (More)
BackgroundStandard treatment of adult Burkitt lymphoma is not defined due to the lack of randomised trials. In this situation, population-based data may represent a useful contribution in order to identify an optimal treatment strategy.Patients and methodsThe aims of this study were to investigate the outcome for adult HIV-negative BL with different chemotherapy regimens, and to assess possible improvement within the time frame of the study. The study population was identified through the Swedish and Danish lymphoma registries 2000-2009.ResultsA total of 258 patients were identified. Since 2000, overall survival (OS) improved significantly only for younger patients (<65 years). Intensive regimens such as the Berlin-Frankfurt-Münster, hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, and cytarabine (CODOX-M/IVAC) were associated with a favourable 2-year OS of 82%, 83%, and 69%, respectively. The low-intensive CHOP/CHOEP regimens achieved a 2-year OS of 38.8%, confirming their inadequacy for the treatment of BL. In a multivariate analysis, rituximab was not significantly associated with improved OS.ConclusionsIn this population-based retrospective series of adult BL, intensive chemotherapy regimens were associated with favourable outcome. The impact of the addition of rituximab remains uncertain and warrants further investigation. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of Oncology
volume
24
issue
7
pages
1879 - 1886
publisher
Oxford University Press
external identifiers
  • wos:000321881600025
  • pmid:23446093
  • scopus:84883751931
  • pmid:23446093
ISSN
1569-8041
DOI
10.1093/annonc/mdt058
language
English
LU publication?
yes
id
14fb3fb4-6b7a-42d7-9d17-1805793f1f33 (old id 3628801)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23446093?dopt=Abstract
date added to LUP
2016-04-01 10:03:25
date last changed
2022-03-19 08:54:26
@article{14fb3fb4-6b7a-42d7-9d17-1805793f1f33,
  abstract     = {{BackgroundStandard treatment of adult Burkitt lymphoma is not defined due to the lack of randomised trials. In this situation, population-based data may represent a useful contribution in order to identify an optimal treatment strategy.Patients and methodsThe aims of this study were to investigate the outcome for adult HIV-negative BL with different chemotherapy regimens, and to assess possible improvement within the time frame of the study. The study population was identified through the Swedish and Danish lymphoma registries 2000-2009.ResultsA total of 258 patients were identified. Since 2000, overall survival (OS) improved significantly only for younger patients (&lt;65 years). Intensive regimens such as the Berlin-Frankfurt-Münster, hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) and cyclophosphamide, vincristine, doxorubicin, methotrexate, ifosfamide, etoposide, and cytarabine (CODOX-M/IVAC) were associated with a favourable 2-year OS of 82%, 83%, and 69%, respectively. The low-intensive CHOP/CHOEP regimens achieved a 2-year OS of 38.8%, confirming their inadequacy for the treatment of BL. In a multivariate analysis, rituximab was not significantly associated with improved OS.ConclusionsIn this population-based retrospective series of adult BL, intensive chemotherapy regimens were associated with favourable outcome. The impact of the addition of rituximab remains uncertain and warrants further investigation.}},
  author       = {{Wästerlid, Tove and Brown, P N and Hagberg, Oskar and Hagberg, H and Pedersen, L M and D'Amore, F and Jerkeman, Mats}},
  issn         = {{1569-8041}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{1879--1886}},
  publisher    = {{Oxford University Press}},
  series       = {{Annals of Oncology}},
  title        = {{Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.}},
  url          = {{https://lup.lub.lu.se/search/files/1520861/3812607.pdf}},
  doi          = {{10.1093/annonc/mdt058}},
  volume       = {{24}},
  year         = {{2013}},
}